Latvia
Tuberculosis profile
| High MDR-TB burden |
Population  2012 2.1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.053 (0.052–0.054) 2.6 (2.5–2.6)
Mortality (HIV+TB only) 0.017 (0.012–0.021) 0.8 (0.6–1)
Prevalence  (includes HIV+TB) 1.6 (0.78–2.6) 76 (38–127)
Incidence  (includes HIV+TB) 1.1 (1–1.2) 53 (49–58)
Incidence (HIV+TB only) 0.1 (0.093–0.11) 5 (4.5–5.4)
Case detection, all forms (%) 87 (80–95)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 342 (39) Relapse 79 (70)
Smear-negative 429 (49) Treatment after failure 5 (4)
Smear-unknown / not done 9 (1) Treatment after default 16 (14)
Extrapulmonary 100 (11) Other 13 (12)
Other 0 (0)      
Total new 880   Total retreatment 113  
           
Other (history unknown) 0        
Total new and relapse 959   Total cases notified 993  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 3.1 1.8 1.3
Age < 15 1 25 30
Laboratories 2012
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 9.7
Drug susceptibility testing (per 5 million population) 2.4
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 73   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 86  
Retreatment 51  
TB/HIV 2012 Number (%)
TB patients with known HIV status 844 (85)
HIV-positive TB patients 114 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 45 (39)
HIV-positive TB patients on antiretroviral therapy (ART) 65 (57)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 11 (8.8–14) 32 (23–42)
MDR-TB cases among notified pulmonary
TB cases
87 (69–110) 36 (26–48)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 666 (97%) 100 (88%) 766
Laboratory-confirmed MDR-TB cases 74 32 110
Patients started on MDR-TB treatment     110
Financing TB control 2013
National TB programme budget (US$ millions) 4.8
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-19 Data: www.who.int/tb/data